Unknown

Dataset Information

0

Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.


ABSTRACT:

Background aims

Preferentially expressed antigen in melanoma (PRAME) is a cancer/testis antigen that is overexpressed in many human malignancies and poorly expressed or absent in healthy tissues, making it a good target for anti-cancer immunotherapy. Development of an effective off-the-shelf adoptive T-cell therapy for patients with relapsed or refractory solid tumors and hematological malignancies expressing PRAME antigen requires the identification of major histocompatibility complex (MHC) class I and II PRAME antigens recognized by the tumor-associated antigen (TAA) T-cell product. The authors therefore set out to extend the repertoire of HLA-restricted PRAME peptide epitopes beyond the few already characterized.

Methods

Peptide libraries of 125 overlapping 15-mer peptides spanning the entire PRAME protein sequence were used to identify HLA class I- and II-restricted epitopes. The authors also determined the HLA restriction of the identified epitopes.

Results

PRAME-specific T-cell products were successfully generated from peripheral blood mononuclear cells of 12 healthy donors. Ex vivo-expanded T cells were polyclonal, consisting of both CD4+ and CD8+ T cells, which elicited anti-tumor activity in vitro. Nine MHC class I-restricted PRAME epitopes were identified (seven novel and two previously described). The authors also characterized 16 individual 15-mer peptide sequences confirmed as CD4-restricted epitopes.

Conclusions

TAA T cells derived from healthy donors recognize a broad range of CD4+ and CD8+ HLA-restricted PRAME epitopes, which could be used to select suitable donors for generating off-the-shelf TAA-specific T cells.

SUBMITTER: Stanojevic M 

PROVIDER: S-EPMC8316284 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.

Stanojevic Maja M   Hont Amy B AB   Geiger Ashley A   O'Brien Samuel S   Ulrey Robert R   Grant Melanie M   Datar Anushree A   Lee Ping-Hsien PH   Lang Haili H   Cruz Conrad R Y CRY   Hanley Patrick J PJ   Barrett A John AJ   Keller Michael D MD   Bollard Catherine M CM  

Cytotherapy 20210405 8


<h4>Background aims</h4>Preferentially expressed antigen in melanoma (PRAME) is a cancer/testis antigen that is overexpressed in many human malignancies and poorly expressed or absent in healthy tissues, making it a good target for anti-cancer immunotherapy. Development of an effective off-the-shelf adoptive T-cell therapy for patients with relapsed or refractory solid tumors and hematological malignancies expressing PRAME antigen requires the identification of major histocompatibility complex (  ...[more]

Similar Datasets

| S-EPMC5465675 | biostudies-literature
| S-EPMC2323292 | biostudies-literature
| S-EPMC10214068 | biostudies-literature
| S-EPMC10577170 | biostudies-literature
| S-EPMC3401035 | biostudies-literature
| S-EPMC2759652 | biostudies-literature
| S-EPMC7378236 | biostudies-literature
| S-EPMC8039679 | biostudies-literature
| S-EPMC8106073 | biostudies-literature
| S-EPMC11350539 | biostudies-literature